Overall, our data demonstrate a detrimental role of OPN in BBB function particularly at early acute stages and suggest OPN as a novel therapeutic target in acute ischemic stroke based on BBB improvement and rescue in ischemic stroke with anti-OPN antibody therapy (Fig. 9b). This evidence concerns the gene SPP1 and ischemic stroke.